$ENVA

Fisher David sold $6.6M of ENVA

Fisher David (Executive Chairman) sold 28,500 shares of Enova International, Inc. (ENVA) at an average of $231.49 ($231.45–$231.51, $6.60M total) across 2 trades over 2026-07-14 to 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fisher David
Published Jul 16, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ENVA
Neutral
medium confidence
Mentioned
$ENVA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ENVANeutralLow
01

Why it matters

The disclosure updates the insider’s post-sale holdings and confirms the sale was executed via an open-market transaction under a pre-arranged 10b5-1 plan.

02

Market read

This is a routine insider-sale filing with limited incremental fundamental information due to the 10b5-1 plan.

03

What to watch

Traders may overreact to insider sales; the key differentiator here is the explicitly stated pre-arranged 10b5-1 plan, which often reduces informational content.

Relevance 5/10Novelty 4/10Timing: SEC Form 4 filed 2026-07-16 after-hours.

Background

The article is an SEC Form 4 insider transaction disclosure for Enova International, Inc.

Company-level read

Ticker impact

$ENVANeutralMedium confidence
Context

Enova executive chairman David Fisher sold 28,500 shares in open-market trades for about $6.6M under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should be muted given the 10b5-1 structure.

Evidence & confidence

The filing provides exact trade dates, share count, and value, but the presence of a pre-arranged 10b5-1 plan typically lowers interpretive weight for fundamentals.

Market effects

Minimal, as this is a single-company insider transaction without sector-wide disclosures.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity needs rather than a bearish view on Enova’s prospects.

Key entities

  • Enova International, Inc.

    Company whose executive chairman reported open-market share sales on Form 4.

  • Fisher David

    Executive Chairman and officer/director who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ENVAMed

Citizens Cuts Enova’s Price Target after its Bank Deal Falls Apart

Citizens analyst David Scharf cut Enova's (NYSE:ENVA) price target to $215 from $270 after it abandoned a bank acquisition deal. Enova cited unclear standards and slow approvals. The company reaffirmed its guidance for 25% revenue growth and 30% adjusted EPS growth in Q3. For the full year, it expects 20-25% revenue growth and 30-35% adjusted EPS growth. Enova reported strong Q2 results with 22% revenue growth and 33% adjusted EPS growth. The company plans to accelerate share repurchases.

$ENVAMed

Why Enova International Stock Was Plummeting This Week

Enova International (NYSE: ENVA) withdrew applications for banking licenses, causing its stock to drop nearly 20% week-to-date. The company cited unclear authorization processes and plans to focus on its existing business. Enova reaffirmed its 2026 revenue growth forecast of 20-25% and adjusted net income per share growth of 30-35%.